Camrelizumab plus chemotherapy versus chemoradiotherapy as neoadjuvant therapy for resectable esophageal squamous cell carcinoma: Phase 2 randomized trial (REVO).

This multicenter, randomized phase 2 trial compared neoadjuvant camrelizumab plus chemotherapy (ICT) versus chemoradioth...

Continue ReadingCamrelizumab plus chemotherapy versus chemoradiotherapy as neoadjuvant therapy for resectable esophageal squamous cell carcinoma: Phase 2 randomized trial (REVO).